Episode: Paul Dabrowski Gets Candid About the Past, Present, and Future of Synthego


CRISPR Cuts Logo
Subscribe
Paul Dabrowski Gets Candid About the Past, Present, and Future of Synthego

In this interview, Paul Dabrowski, CEO of Synthego, talks about how Synthego got started, his mantra behind leading the company, and future directions. He also offers insights into Synthego’s unique capabilities⁠—the powerful combination of engineering and biology that enable scaling.



CRISPR Cuts
Users who viewed this episode also viewed...

CRISPR Cuts > Reed Kelso Strives to Enable CRISPR Access For All Scientists

Reed Kelso, Head of Cell Engineering Research and Applications at Synthego, is a bio-wizard. In this episode, Kevin & Minu catch up with Reed about his role at Synthego and the day-to-day operations at the fast paced start-up. Reed talks about the revolutionary engineered cells products that he and his team recently launched & the hard work behind this amazing achievement...

CRISPR Cuts > Dana Foss is Solving the CRISPR Delivery Problem to Advance Therapeutics

CRISPR has great potential in therapeutics, but CRISPR delivery in vivo remains a challenge. Researcher Dana Foss discusses her lab’s novel approach for specific delivery of CRISPR components in cells and tissues.

CRISPR Cuts > Alex Philippidis Reviews Trends in Biopharma & Biotech Market

Biotech and biopharma companies are in a phase of accelerated growth. Alex Philippidis, a science journalist at Genetic Engineering & Biotechnology News discusses the changing face of big pharma, biotech, and CRISPR gene editing industries, as they raise more money and the world changes around them.
Comments (0)

Login or Sign up to leave a comment.

Log in
Sign up

Be the first to comment.